Adrianus J de Langen
Overview
Explore the profile of Adrianus J de Langen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1941
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ernst S, Aldea M, von der Thusen J, de Langen A, Smit E, Paats M, et al.
Nat Rev Clin Oncol
. 2025 Mar;
PMID: 40087401
Advances in targeted therapies for patients with non-small-cell lung cancer have substantially improved the outcomes of those with actionable alterations in certain oncogenic driver genes. However, acquired resistance to these...
2.
van der Gaag S, Jordens T, Yaqub M, Grijseels R, van Valkengoed D, de Langen E, et al.
CPT Pharmacometrics Syst Pharmacol
. 2025 Feb;
PMID: 40009553
Osimertinib, a tyrosine kinase inhibitor (TKI), treats non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. However, its efficacy may vary due to heterogeneous drug distribution, assessable...
3.
Qi Z, Tokuhiro S, Odegaard J, Wienke S, Karnoub M, Feng W, et al.
J Mol Diagn
. 2025 Jan;
27(2):119-129.
PMID: 39880580
This study demonstrates the analytical and clinical validity of the approved (United States and Japan) plasma-based Guardant360 companion diagnostic (CDx) test for selecting patients with human epidermal growth factor receptor...
4.
Verkerk K, van der Wel T, Zeverijn L, Geurts B, Spiekman I, de Wit G, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5323-5332.
PMID: 39352721
Purpose: To provide patients with MET-mutated advanced non-small cell lung cancer (METmut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in this setting, and find potential...
5.
van der Wel J, Boelens M, Jebbink M, Smulders S, Maas K, Luitse M, et al.
Neuro Oncol
. 2024 Aug;
26(12):2316-2327.
PMID: 39110039
Background: Diagnosis and treatment of leptomeningeal metastases (LM) in epidermal growth factor receptor mutation-positive (EGFRm +) non-small-cell lung carcinoma (NSCLC) is challenging. We aimed to identify resistance mechanisms (RM) to...
6.
Op t Hoog C, Mehra N, Maliepaard M, Bol K, Gelderblom H, Sonke G, et al.
Lancet Oncol
. 2024 Aug;
25(8):e340-e351.
PMID: 39089312
Historically, dose selection of anticancer drugs has mainly been based on establishing the maximum tolerated dose in phase 1 clinical trials with a traditional 3 plus 3 design. In the...
7.
Miedema I, Pouw J, Kwakman A, Zwezerijnen G, Huisman M, Timmer F, et al.
J Immunother Cancer
. 2024 Jun;
12(6).
PMID: 38886117
Introduction: Immune checkpoint inhibitors (ICIs) can elicit anticancer immune responses, but predictive biomarkers are needed. We measured programmed death ligand 1 (PD-L1) expression in organs and lymph nodes using F-BMS-986192...
8.
Samsom K, Bosch L, Schipper L, Schout D, Roepman P, Boelens M, et al.
Nat Protoc
. 2023 Dec;
19(3):700-726.
PMID: 38092944
Two decades after the genomics revolution, oncology is rapidly transforming into a genome-driven discipline, yet routine cancer diagnostics is still mainly microscopy based, except for tumor type-specific predictive molecular tests....
9.
Miedema I, Wijngaarden J, Pouw J, Zwezerijnen G, Sebus H, Smit E, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067257
Introduction: Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies ([Zr]Zr-mAbs)) can be used to study the biodistribution of mAbs targeting the immune system. The measured uptake consists of target-specific and...
10.
Burgers V, Reuvers M, Taphoorn M, Kok M, de Langen A, van den Bent M, et al.
Support Care Cancer
. 2023 Nov;
31(12):721.
PMID: 38008874
Purpose: Treatment advancements have improved life expectancy for adolescents and young adults (AYAs) with an uncertain and/or poor cancer prognosis (UPCP) and change clinical practice. This improved survival requires a...